Echocardiography, spirometry, and systemic acute-phase inflammatory proteins in smokers with COPD or CHF: An observational study

Bianca Beghé, Alessia Verduri, Barbara Bottazzi, Mariarita Stendardo, Alessandro Fucili, Sara Balduzzi, Chiara Leuzzi, Alberto Papi, Alberto Mantovani, Leonardo M. Fabbri, Claudio Ceconi, Piera Boschetto

Research output: Contribution to journalArticle

Abstract

Chronic obstructive pulmonary disease (COPD) and chronic heart failure (CHF) may coexist in elderly patients with a history of smoking. Low-grade systemic inflammation induced by smoking may represent the link between these 2 conditions. In this study, we investigated left ventricular dysfunction in patients primarily diagnosed with COPD, and nonreversible airflow limitation in patients primarily diagnosed with CHF. The levels of circulating high-sensitive Creactive protein (Hs-CRP), pentraxin 3 (PTX3), interleukin-1β (IL-1 β), and soluble type II receptor of IL-1 (sIL-1RII) were also measured as markers of systemic inflammation in these 2 cohorts. Patients aged ≥50 years and with ≥10 pack years of cigarette smoking who presented with a diagnosis of stable COPD (n=70) or stable CHF (n=124) were recruited. All patients underwent echocardiography, N-terminal pro-hormone of brain natriuretic peptide measurements, and post-bronchodilator spirometry. Plasma levels of Hs-CRP, PTX3, IL-1 β, and sIL-1RII were determined by using a sandwich enzyme-linked immuno-sorbent assay in all patients and in 24 healthy smokers (control subjects). Although we were unable to find a single COPD patient with left ventricular dysfunction, we found nonreversible airflow limitation in 34% of patients with CHF. On the other hand, COPD patients had higher plasma levels of Hs-CRP, IL1 β, and sIL-1RII compared with CHF patients and control subjects (p <0.05). None of the inflammatory biomarkers was different between CHF patients and control subjects. In conclusion, although the COPD patients had no evidence of CHF, up to one third of patients with CHF had airflow limitation, suggesting that routine spirometry is warranted in patients with CHF, whereas echocardiography is not required in well characterized patients with COPD. Only smokers with COPD seem to have evidence of systemic inflammation.

Original languageEnglish
Article numbere80166
JournalPLoS One
Volume8
Issue number11
DOIs
Publication statusPublished - Nov 11 2013

Fingerprint

Echocardiography
Pulmonary diseases
Acute-Phase Proteins
Spirometry
echocardiography
observational studies
heart failure
respiratory tract diseases
Chronic Obstructive Pulmonary Disease
Observational Studies
Heart Failure
Proteins
proteins
Interleukin-1
interleukin-1
air flow
Interleukin-1 Type II Receptors
inflammation
Smoking
smoking (food products)

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Echocardiography, spirometry, and systemic acute-phase inflammatory proteins in smokers with COPD or CHF : An observational study. / Beghé, Bianca; Verduri, Alessia; Bottazzi, Barbara; Stendardo, Mariarita; Fucili, Alessandro; Balduzzi, Sara; Leuzzi, Chiara; Papi, Alberto; Mantovani, Alberto; Fabbri, Leonardo M.; Ceconi, Claudio; Boschetto, Piera.

In: PLoS One, Vol. 8, No. 11, e80166, 11.11.2013.

Research output: Contribution to journalArticle

Beghé, B, Verduri, A, Bottazzi, B, Stendardo, M, Fucili, A, Balduzzi, S, Leuzzi, C, Papi, A, Mantovani, A, Fabbri, LM, Ceconi, C & Boschetto, P 2013, 'Echocardiography, spirometry, and systemic acute-phase inflammatory proteins in smokers with COPD or CHF: An observational study', PLoS One, vol. 8, no. 11, e80166. https://doi.org/10.1371/journal.pone.0080166
Beghé, Bianca ; Verduri, Alessia ; Bottazzi, Barbara ; Stendardo, Mariarita ; Fucili, Alessandro ; Balduzzi, Sara ; Leuzzi, Chiara ; Papi, Alberto ; Mantovani, Alberto ; Fabbri, Leonardo M. ; Ceconi, Claudio ; Boschetto, Piera. / Echocardiography, spirometry, and systemic acute-phase inflammatory proteins in smokers with COPD or CHF : An observational study. In: PLoS One. 2013 ; Vol. 8, No. 11.
@article{4fdf3da9538a484d869530656d67a262,
title = "Echocardiography, spirometry, and systemic acute-phase inflammatory proteins in smokers with COPD or CHF: An observational study",
abstract = "Chronic obstructive pulmonary disease (COPD) and chronic heart failure (CHF) may coexist in elderly patients with a history of smoking. Low-grade systemic inflammation induced by smoking may represent the link between these 2 conditions. In this study, we investigated left ventricular dysfunction in patients primarily diagnosed with COPD, and nonreversible airflow limitation in patients primarily diagnosed with CHF. The levels of circulating high-sensitive Creactive protein (Hs-CRP), pentraxin 3 (PTX3), interleukin-1β (IL-1 β), and soluble type II receptor of IL-1 (sIL-1RII) were also measured as markers of systemic inflammation in these 2 cohorts. Patients aged ≥50 years and with ≥10 pack years of cigarette smoking who presented with a diagnosis of stable COPD (n=70) or stable CHF (n=124) were recruited. All patients underwent echocardiography, N-terminal pro-hormone of brain natriuretic peptide measurements, and post-bronchodilator spirometry. Plasma levels of Hs-CRP, PTX3, IL-1 β, and sIL-1RII were determined by using a sandwich enzyme-linked immuno-sorbent assay in all patients and in 24 healthy smokers (control subjects). Although we were unable to find a single COPD patient with left ventricular dysfunction, we found nonreversible airflow limitation in 34{\%} of patients with CHF. On the other hand, COPD patients had higher plasma levels of Hs-CRP, IL1 β, and sIL-1RII compared with CHF patients and control subjects (p <0.05). None of the inflammatory biomarkers was different between CHF patients and control subjects. In conclusion, although the COPD patients had no evidence of CHF, up to one third of patients with CHF had airflow limitation, suggesting that routine spirometry is warranted in patients with CHF, whereas echocardiography is not required in well characterized patients with COPD. Only smokers with COPD seem to have evidence of systemic inflammation.",
author = "Bianca Begh{\'e} and Alessia Verduri and Barbara Bottazzi and Mariarita Stendardo and Alessandro Fucili and Sara Balduzzi and Chiara Leuzzi and Alberto Papi and Alberto Mantovani and Fabbri, {Leonardo M.} and Claudio Ceconi and Piera Boschetto",
year = "2013",
month = "11",
day = "11",
doi = "10.1371/journal.pone.0080166",
language = "English",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "11",

}

TY - JOUR

T1 - Echocardiography, spirometry, and systemic acute-phase inflammatory proteins in smokers with COPD or CHF

T2 - An observational study

AU - Beghé, Bianca

AU - Verduri, Alessia

AU - Bottazzi, Barbara

AU - Stendardo, Mariarita

AU - Fucili, Alessandro

AU - Balduzzi, Sara

AU - Leuzzi, Chiara

AU - Papi, Alberto

AU - Mantovani, Alberto

AU - Fabbri, Leonardo M.

AU - Ceconi, Claudio

AU - Boschetto, Piera

PY - 2013/11/11

Y1 - 2013/11/11

N2 - Chronic obstructive pulmonary disease (COPD) and chronic heart failure (CHF) may coexist in elderly patients with a history of smoking. Low-grade systemic inflammation induced by smoking may represent the link between these 2 conditions. In this study, we investigated left ventricular dysfunction in patients primarily diagnosed with COPD, and nonreversible airflow limitation in patients primarily diagnosed with CHF. The levels of circulating high-sensitive Creactive protein (Hs-CRP), pentraxin 3 (PTX3), interleukin-1β (IL-1 β), and soluble type II receptor of IL-1 (sIL-1RII) were also measured as markers of systemic inflammation in these 2 cohorts. Patients aged ≥50 years and with ≥10 pack years of cigarette smoking who presented with a diagnosis of stable COPD (n=70) or stable CHF (n=124) were recruited. All patients underwent echocardiography, N-terminal pro-hormone of brain natriuretic peptide measurements, and post-bronchodilator spirometry. Plasma levels of Hs-CRP, PTX3, IL-1 β, and sIL-1RII were determined by using a sandwich enzyme-linked immuno-sorbent assay in all patients and in 24 healthy smokers (control subjects). Although we were unable to find a single COPD patient with left ventricular dysfunction, we found nonreversible airflow limitation in 34% of patients with CHF. On the other hand, COPD patients had higher plasma levels of Hs-CRP, IL1 β, and sIL-1RII compared with CHF patients and control subjects (p <0.05). None of the inflammatory biomarkers was different between CHF patients and control subjects. In conclusion, although the COPD patients had no evidence of CHF, up to one third of patients with CHF had airflow limitation, suggesting that routine spirometry is warranted in patients with CHF, whereas echocardiography is not required in well characterized patients with COPD. Only smokers with COPD seem to have evidence of systemic inflammation.

AB - Chronic obstructive pulmonary disease (COPD) and chronic heart failure (CHF) may coexist in elderly patients with a history of smoking. Low-grade systemic inflammation induced by smoking may represent the link between these 2 conditions. In this study, we investigated left ventricular dysfunction in patients primarily diagnosed with COPD, and nonreversible airflow limitation in patients primarily diagnosed with CHF. The levels of circulating high-sensitive Creactive protein (Hs-CRP), pentraxin 3 (PTX3), interleukin-1β (IL-1 β), and soluble type II receptor of IL-1 (sIL-1RII) were also measured as markers of systemic inflammation in these 2 cohorts. Patients aged ≥50 years and with ≥10 pack years of cigarette smoking who presented with a diagnosis of stable COPD (n=70) or stable CHF (n=124) were recruited. All patients underwent echocardiography, N-terminal pro-hormone of brain natriuretic peptide measurements, and post-bronchodilator spirometry. Plasma levels of Hs-CRP, PTX3, IL-1 β, and sIL-1RII were determined by using a sandwich enzyme-linked immuno-sorbent assay in all patients and in 24 healthy smokers (control subjects). Although we were unable to find a single COPD patient with left ventricular dysfunction, we found nonreversible airflow limitation in 34% of patients with CHF. On the other hand, COPD patients had higher plasma levels of Hs-CRP, IL1 β, and sIL-1RII compared with CHF patients and control subjects (p <0.05). None of the inflammatory biomarkers was different between CHF patients and control subjects. In conclusion, although the COPD patients had no evidence of CHF, up to one third of patients with CHF had airflow limitation, suggesting that routine spirometry is warranted in patients with CHF, whereas echocardiography is not required in well characterized patients with COPD. Only smokers with COPD seem to have evidence of systemic inflammation.

UR - http://www.scopus.com/inward/record.url?scp=84893186495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893186495&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0080166

DO - 10.1371/journal.pone.0080166

M3 - Article

C2 - 24244639

AN - SCOPUS:84893186495

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 11

M1 - e80166

ER -